Adial Pharmaceuticals Reports Decreased Net Loss and Increased Cash Reserves in Q3 2025

Adial Pharmaceuticals, Inc. reported a net loss of $1.79 million for the third quarter of 2025, a decrease from a loss of $2.19 million in the same period of 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $5.98 million, significantly improved from a loss of $11.13 million during the same timeframe in 2024. The reduction in losses is attributed to a decrease in operating expenses, which totaled $1.76 million for the quarter, down from $2.21 million a year earlier, and $5.91 million for the nine months, compared to $6.34 million in 2024. The company’s cash and cash equivalents increased to $4.61 million as of September 30, 2025, up from $3.75 million at the end of 2024.

Adial's research and development expenses saw a notable decline, dropping by 50% to $521,000 for the third quarter and by 20% to $2 million for the nine months ended September 30, 2025. This decrease is primarily due to reduced clinical activity compared to the previous year. General and administrative expenses increased slightly by 5% to $1.24 million for the third quarter and by 2% to $3.91 million for the nine months, reflecting higher compensation costs. The company also recognized a milestone payment of $150,000 from its equity method investment in Adovate, LLC, contributing to a more favorable financial position.

In terms of strategic developments, Adial completed the merger of its subsidiary Purnovate into the parent company during the third quarter of 2025. The company has focused its resources on the development of its lead product candidate, AD04, which is aimed at treating alcohol use disorder. Following a recent End of Phase 2 meeting with the FDA, Adial is preparing for a Phase 3 clinical trial, expected to commence in the first half of 2026, contingent on securing adequate funding.

Operationally, Adial's total assets increased to $5.66 million as of September 30, 2025, compared to $5.04 million at the end of 2024. The company’s stockholders' equity also rose to $4.51 million, up from $4.07 million. The number of shares outstanding increased significantly to 23.84 million from 6.47 million, reflecting recent equity financing activities. The company has engaged in various financing strategies, including warrant inducement agreements and at-the-market offerings, to bolster its capital position, although it continues to face substantial doubt regarding its ability to sustain operations without additional funding.

Looking ahead, Adial Pharmaceuticals acknowledges the need for further capital to support its ongoing operations and development plans. The company is actively pursuing financing options, including equity offerings and potential collaborations, to ensure it can meet its operational commitments and continue its clinical development programs. The management has expressed concerns about the company's ability to continue as a going concern if additional funding is not secured in a timely manner.